Risankizumab Study for Chronic Plaque Psoriasis (64 Weeks)

Adults aged 18 years or older previously diagnosed with moderate to severe chronic plaque psoriasis, may qualify to participate. Individuals must be on labeled secukinumab or ixekizumab treatment (for at least 6 months) and are experiencing a sub-optimal response, at the time of screening. Psoriasis involving 3% to less than 10% body surface area (BSA) is also required.

Participants will receive investigational risankizumab treatment via subcutaneous injection. Investigational medication and study-related care will be provided at no cost. Reimbursement for study-related expenses will also be provided.

Study participation will last about 64 weeks and involve about 8 visits to the study centre, plus a follow-up phone call.

Call the study centre near you, or register now.

Learn more about
Psoriasis
Register Now!

Participating Locations

AR

  • Sorry no locations are available in this country.

CA

  • Sorry no locations are available in this country.

CL

  • Sorry no locations are available in this country.

MX

  • Sorry no locations are available in this country.

US

  • Sorry no locations are available in this country.

Register for
Active Studies!

Register

All information about you will be kept confidential.

If there are no active studies for your condition, we will keep your information and contact you when a new study starts in your area.

By registering you are consenting to the terms and conditions of our privacy policy.

Find the clinic near you:

Why Take Part In a Clinical Study?

Regulatory agencies like Health Canada, Australia's Therapeutic Goods Administration and the FDA require that Clinical Research Trials be conducted in order to develop new treatments, preventions and devices for diseases or conditions. Clinical Research Trials are also referred to as Clinical Studies or Clinical Trials. read more